2016-63-9

Basic information

• Product Name: BAMIFYLLINE
• Synonyms: BAMIFYLLINE;8-benzyl-7-(2-(N-ethyl-2-hydroxyethylamino)ethyl)theophylline;8-BENZYL-7-(2-(HYDROXYETHYL)AMINO)ETHYL)THEOPHYLLINE;8102 CB;8102CB;Bamiphylline;Bax-2739Z;CB-8102
• CAS NO: 2016-63-9
• Molecular Formula: C20H27N5O3
• Molecular Weight: 385.46
• Mol File: 2016-63-9.mol
• Article Data: 1

Chemical Properties

• Melting Point: 80-80.5°
• Boiling Point: 618.981 °C at 760 mmHg
• Flash Point: 328.148 °C
• Appearance: /
• Density: 1.25
• Vapor Pressure: 3.51E-16mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform (Very Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 14.73±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: BAMIFYLLINE(CAS DataBase Reference)
• NIST Chemistry Reference: BAMIFYLLINE(2016-63-9)
• EPA Substance Registry System: BAMIFYLLINE(2016-63-9)

Safety Data

• Hazardous Substances Data: 2016-63-9(Hazardous Substances Data)

Usage

Description

Bamifylline, belonging to the xanthine chemical class, is a pharmaceutical compound that functions as a selective adenosine A1 receptor antagonist. It possesses bronchodilator properties and is utilized in the treatment of various respiratory conditions.

Uses

Used in Pharmaceutical Industry:
Bamifylline is used as a bronchodilator for the treatment of respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). Its bronchodilating action helps in relaxing the smooth muscles of the airways, thereby improving airflow and reducing symptoms like wheezing and shortness of breath.
Used in Research and Development:
As a selective adenosine A1 receptor antagonist, Bamifylline is also used in research and development for studying the role of adenosine receptors in various physiological processes and their potential therapeutic applications in conditions like neurodegenerative diseases, cardiovascular disorders, and inflammation.

Originator

Bamifylline,ZYF Pharm Chemical

Manufacturing Process

A mixture of 100 kg of 8-benzyltheophilline, 36 L of N-ethylethanolamine, 300 L of 1,2-dichlorethane and 71 kg of sodium carbonate was refluxed for 24 hours. Then 36 L of N-ethylethanolamine was added and the reaction mixture was refluxed. After cooling to the mixture was added the water and hydrochloric acid. The organic phase was extracted with hydrochloric acid. The acidic phase was neutralized with sodium carbonate and the 7-(N-ethyl-N-β- hydroxyethylaminoethyl)-8-benzyltheophilline was extracted with dichloromethane. The solvent was evaporated and the free base of 7-(N-ethyl- N-β-hydroxyethylaminoethyl)-8-benzyltheophilline was dissolved in methanol. Hydrochloride of 7-(N-ethyl-N-β-hydroxyethylaminoethyl)-8-benzyltheophilline was obtained by addition to the solution the hydrochloric acid; yield 81%, melting point 185-186°C.

Therapeutic Function

Bronchodilator, Coronary vasodilator

InChI:InChI=1/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3

Upstream product

• 2879-15-4 8-benzyltheophylline 

Relevant articles and documents

Process for converting a xanthine ring or xanthine ring derivatives into dialkylaminoxanthine derivatives

The invention relates to a process for the preparation of bamifylline or etamiphylline, in which a mixture comprising: a) theophylline or 8-benzyltheophyl-line; b) an alkyl dihalide; and c) a molar excess of an amine is reacted in the presence of a weak b